Solara Active Pharma Sciences · NSE: SOLARA · BSE: 541540
Q1 FY27 results · Apr–Jun 2026
Solara Active Pharma Sciences reported revenue from operations of ₹381.60 crore (up 19.6% from Q1 FY26) and net profit of ₹16.31 crore (up 55.0% from Q1 FY26) for Q1 FY27 (Apr–Jun 2026), on a consolidated basis.
| Item | Q1 FY27 | Q1 FY26 | YoY | Q4 FY26 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 381.60 | 319.15 | +19.6% | 387.29 | −1.5% |
| Other income | 2.69 | 0.98 | +174.5% | 4.69 | −42.6% |
| Total income | 384.29 | 320.13 | +20.0% | 391.98 | −2.0% |
| Profit before tax | 16.31 | 10.52 | +55.0% | 9.60 | +69.9% |
| Net profit for the period | 16.31 | 10.52 | +55.0% | 9.60 | +69.9% |
| EPS, basic (₹) | 3.52 | 2.46 | +43.1% | 2.20 | +60.0% |
| Net margin (%) | 4.3 | 3.3 | 2.5 |
| Item | Q1 FY27 | Q1 FY26 | YoY | Q4 FY26 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 381.60 | 319.15 | +19.6% | 387.29 | −1.5% |
| Other income | 1.92 | 0.98 | +95.9% | 4.42 | −56.6% |
| Total income | 383.52 | 320.13 | +19.8% | 391.71 | −2.1% |
| Profit before tax | 16.99 | 10.53 | +61.3% | 9.73 | +74.6% |
| Net profit for the period | 16.99 | 10.53 | +61.3% | 9.73 | +74.6% |
| EPS, basic (₹) | 3.67 | 2.46 | +49.2% | 2.23 | +64.6% |
| Net margin (%) | 4.5 | 3.3 | 2.5 |
Consolidated
- Filed with BSE
- 23 Jul 2026, 17:16 IST
- Board meeting
- 23 Jul 2026
- Period
- 01 Apr 2026 to 30 Jun 2026
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 23 Jul 2026, 17:16 IST
- Board meeting
- 23 Jul 2026
- Period
- 01 Apr 2026 to 30 Jun 2026
- Review status
- Unaudited
- Source
- XBRL filing on BSE